nach oben

Erschienen in:

01.07.2021 | News item

Atezolizumab: risk of severe cutaneous adverse reactions

Erschienen in: Reactions Weekly | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Excerpt

Atezolizumab [Tecentriq] and other immune-stimulatory cancer drugs are associated with a risk of severe cutaneous adverse reactions (SCARs) including Stevens-Johnsons syndrome (SJS) and toxic epidermal necrolysis (TEN), reports the UK Medicines and Healthcare products Regulatory Agency (MHRA). …

Medicines and Healthcare products Regulatory Agency. Atezolizumab (Tecentriq) and other immune-stimulatory anti-cancer drugs: risk of severe cutaneous adverse reactions (SCARs) Internet Document : 17 Jun 2021. Available from: URL: https://www.gov.uk/drug-safety-update/atezolizumab-tecentriqv-and-other-immune-stimulatory-anti-cancer-drugs-risk-of-severe-cutaneous-adverse-reactions-scars

Titel: Atezolizumab: risk of severe cutaneous adverse reactions
Publikationsdatum: 01.07.2021
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2021
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-98119-y

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Atezolizumab: risk of severe cutaneous adverse reactions

Excerpt

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Hydralazine/ondansetron/potassium

Haloperidol withdrawal

Antineoplastics

Dabrafenib/trametinib

Isavuconazole/tacrolimus

Prednisolone